Key Takeaways Bausch Health's Q3 EPS of $1.16 and revenues of $2.68B beat consensus estimates.Salix revenues jumped 12%, led by 16% growth in Xifaxan sales on solid demand.Company raised 2025 revenue outlook, now guiding up to $10.050-$10.250B for the year.Bausch Health Companies Inc. (BHC) reported better-than-expected results for the third quarter of 2025. Shares gained 7.3% in after-market hours trading in response to the quarterly performance.Adjusted earnings per share of $1.16 comfortably beat the Zac ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 98-0448205 (State ...

Bausch Health (NYSE:BHC) Q3 2025 Earnings Call October 29, 2025 05:00 PM ET Company ParticipantsMike Nedelcovych - Director Equity ResearchJJ Charhon - CFOLiwen Wang - Equity Research AssociateTom Appio - CEOLes Sulewski - VPGaren Sarafian - VP of Investor RelationsConference Call ParticipantsNone - AnalystNone - AnalystDoug Miehm - Healthcare AnalystMichael Freeman - Equity Research AnalystOperatorGreetings and welcome to the Bausch Health third quarter 2025 earnings conference call. At this time, all part ...

Bausch Health (NYSE:BHC) Q3 2025 Earnings Call October 29, 2025 05:00 PM ET Company ParticipantsMike Nedelcovych - Director Equity ResearchJJ Charhon - CFOLiwen Wang - Equity Research AssociateTom Appio - CEOLes Sulewski - VPGaren Sarafian - VP of Investor RelationsConference Call ParticipantsNone - AnalystNone - AnalystDoug Miehm - Healthcare AnalystMichael Freeman - Equity Research AnalystOperatorGreetings and welcome to the Bausch Health third quarter 2025 earnings conference call. At this time, all part ...

Bausch Health (NYSE:BHC) Q3 2025 Earnings Call October 29, 2025 05:00 PM ET Speaker5Greetings and welcome to the Bausch Health third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. You may be placed into the question queue at any time by pressing star one on your telephone keypad. If anyone should require operator assistance, please press star zero. As a reminder, this conference is being reco ...

3Q 2025 Earnings October 29, 2025 ® ©2025 Bausch Health and/or one of its affiliates. 1 Forward-Looking Statements; Non-GAAP Information Forward-Looking Statements This presentation contains forward-looking information and statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws (collectively, "forward-looking statements"), including, but not limited to, statements relating to Bausch Health Companies Inc.'s ("Bausch Health" or the "Co ...

Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano (877) 281-6642 (toll free) (908) 541-3785 ir@bauschhealth.com corporate.communications@bauschhealth.com BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2025 RESULTS LAVAL, QC, October 29, 2025 – Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2025 financial results and other key updates from the quarter. "The third quarter marks our tenth consecutive quart ...

Third Quarter Consolidated Revenues of $2.68 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $179 million and GAAP Net Income of $181 million Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $986 million, including an $81 million acquired In-Process Research & Development ("IPR&D") charge, up 8% on a Reported basis over the prior year period BAUSCH HEALTH EXCLUDING BAUSCH + LOMB THI ...

Bausch Health (BHC) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on October 29, might help the stock move higher if these key numbers are better than exp ...

Core Viewpoint - Activist investor Jana Partners has acquired a stake in The Cooper Companies and is advocating for strategic alternatives, including a potential merger of its contact-lens division with Bausch + Lomb [1][2] Group 1: Strategic Moves - Jana Partners aims to unlock shareholder value by improving capital allocation and possibly separating Cooper's two distinct business segments [2] - The CEO of Bausch + Lomb has expressed openness to a merger, suggesting it would enhance competition in the global contact-lens market [3][4] Group 2: Financial Performance - CooperCompanies has increased its share repurchase program by $1 billion to a total of $2 billion [1] - CooperVision's third-quarter sales reached $718.4 million, a 6% increase year-over-year, with fourth-quarter sales expected between $700 million and $713 million [7] - CooperSurgical sales rose by 4% to $341.9 million, with fourth-quarter expectations between $350 million and $356 million [8] Group 3: Market Context - Cooper is valued at approximately $14 billion, while Bausch + Lomb has a market capitalization of around $5.3 billion [4][5] - The contact-lens market is competitive, with major players including Cooper, Johnson & Johnson, and Alcon [5]